{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,30]],"date-time":"2026-10-30T02:56:45Z","timestamp":1793329005170,"version":"4.5.0"},"reference-count":26,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"8","content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2025,8]]},"abstract":"<jats:p>Lutetium-177 prostate-specific membrane antigen-617 (Lu-PSMA) has demonstrated efficacy in improving progression-free survival and overall survival in patients with metastatic castration-resistant prostate cancer (mCRPC). Post-treatment single photon emission tomography\/computed tomography (SPECT\/CT) imaging is an emerging tool for monitoring treatment response, enabling the tracking of functional changes during therapy. While quantitative SPECT analysis can predict patient outcomes, qualitative assessments are more practical and time-efficient in clinical settings. This case-based review examines treatment responses based on post-treatment SPECT\/CT imaging, categorizing them into favorable response, progression, and mixed response patterns to improve interpretation and guide therapeutic adjustments, aiming to optimize management of mCRPC with Lu-PSMA therapy.<\/jats:p>","DOI":"10.1097\/rlu.0000000000005986","type":"journal-article","created":{"date-parts":[[2025,5,21]],"date-time":"2025-05-21T05:00:19Z","timestamp":1747803619000},"page":"e453-e460","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":4,"title":["The Role of SPECT\/CT in 177Lu-PSMA-617 Theranostics: Case-based Review of Response and Progression Patterns"],"prefix":"10.1097","volume":"50","author":[{"given":"Alireza","family":"Ghodsi","sequence":"first","affiliation":[{"name":"Department of Radiology, University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0005-9123-4105","authenticated-orcid":false,"given":"Ridvan Arda","family":"Demirci","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Washington"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-0150-5401","authenticated-orcid":false,"given":"Delphine L.","family":"Chen","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Washington"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5451-5726","authenticated-orcid":false,"given":"Peter S.","family":"Nelson","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center"},{"name":"Department of Internal Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael T.","family":"Schweizer","sequence":"additional","affiliation":[{"name":"Clinical Research Division, Fred Hutchinson Cancer Center"},{"name":"Department of Internal Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Evan Y.","family":"Yu","sequence":"additional","affiliation":[{"name":"Department of Internal Medicine, University of Washington, Seattle, WA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Amir","family":"Iravani","sequence":"additional","affiliation":[{"name":"Department of Radiology, University of Washington"},{"name":"Clinical Research Division, Fred Hutchinson Cancer Center"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2025,5,21]]},"reference":[{"key":"R1-20250630","doi-asserted-by":"crossref","first-page":"669","DOI":"10.2967\/jnumed.123.265670","article-title":"What is theranostics","volume":"64","author":"Weber","year":"2023","journal-title":"J Nucl Med"},{"key":"R2-20250630","doi-asserted-by":"crossref","first-page":"581","DOI":"10.1053\/j.semnuclmed.2024.02.007","article-title":"Prostate cancer theranostics with 177Lu-PSMA","volume":"54","author":"Ahmadzadehfar","year":"2024","journal-title":"Semin Nucl Med"},{"key":"R3-20250630","doi-asserted-by":"crossref","first-page":"85","DOI":"10.2967\/jnumed.116.183194","article-title":"German multicenter study investigating 177Lu-PSMA-617 radioligand therapy in advanced prostate cancer patients","volume":"58","author":"Rahbar","year":"2017","journal-title":"J Nucl Med"},{"key":"R4-20250630","doi-asserted-by":"crossref","first-page":"331","DOI":"10.2967\/jnumed.121.262997","article-title":"The history of prostate-specific membrane antigen as a theranostic target in prostate cancer: the cornerstone role of the prostate cancer foundation","volume":"63","author":"Miyahira","year":"2022","journal-title":"J Nucl Med"},{"key":"R5-20250630","doi-asserted-by":"crossref","first-page":"1091","DOI":"10.1056\/NEJMoa2107322","article-title":"Lutetium-177\u2013PSMA-617 for metastatic castration-resistant prostate cancer","volume":"385","author":"Sartor","year":"2021","journal-title":"N Engl J Med"},{"key":"R6-20250630","doi-asserted-by":"crossref","first-page":"157","DOI":"10.1016\/j.eururo.2024.09.017","article-title":"Management of patients with advanced prostate cancer. Report from the 2024 Advanced Prostate Cancer Consensus Conference (APCCC)","volume":"87","author":"Gillessen","year":"2025","journal-title":"Eur Urol"},{"key":"R7-20250630","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1016\/j.eururo.2024.08.021","article-title":"Association of declining prostate-specific antigen levels with clinical outcomes in patients with metastatic castration-resistant prostate cancer receiving [177Lu] Lu-PSMA-617 in the phase 3 VISION trial","volume":"86","author":"Armstrong","year":"2024","journal-title":"Eur Urol"},{"key":"R8-20250630","doi-asserted-by":"crossref","first-page":"221","DOI":"10.2967\/jnumed.122.264398","article-title":"Evaluation of 177Lu-PSMA-617 SPECT\/CT quantitation as a response biomarker within a prospective 177Lu-PSMA-617 and NOX66 combination trial (LuPIN)","volume":"64","author":"Pathmanandavel","year":"2023","journal-title":"J Nucl Med"},{"key":"R9-20250630","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1016\/S1470-2045(24)00135-9","article-title":"[177Lu] Lu-PSMA-617 plus enzalutamide in patients with metastatic castration-resistant prostate cancer (ENZA-p): an open-label, multicentre, randomised, phase 2 trial","volume":"25","author":"Emmett","year":"2024","journal-title":"Lancet Oncol"},{"key":"R10-20250630","first-page":"1651","article-title":"Novel framework for treatment response evaluation using PSMA PET\/CT in patients with metastatic castration-resistant prostate cancer (RECIP 1.0): an international multicenter study","volume":"63","author":"Gafita","year":"2022","journal-title":"J Nucl Med"},{"key":"R11-20250630","doi-asserted-by":"crossref","first-page":"469","DOI":"10.1007\/s00259-020-04934-4","article-title":"Consensus statements on PSMA PET\/CT response assessment criteria in prostate cancer","volume":"48","author":"Fanti","year":"2021","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R12-20250630","first-page":"1945","article-title":"SPECT\/CT in early response assessment of patients with metastatic castration-resistant prostate cancer receiving 177Lu-PSMA-617","volume":"65","author":"Demirci","year":"2024","journal-title":"J Nucl Med"},{"key":"R13-20250630","doi-asserted-by":"crossref","first-page":"410","DOI":"10.2967\/jnumed.122.264677","article-title":"177Lu-PSMA SPECT quantitation at 6 weeks (dose 2) predicts short progression-free survival for patients undergoing 177Lu-PSMA-I&T therapy","volume":"64","author":"John","year":"2023","journal-title":"J Nucl Med"},{"key":"R14-20250630","doi-asserted-by":"crossref","first-page":"52","DOI":"10.1002\/jmrs.227","article-title":"Lutetium 177 PSMA radionuclide therapy for men with prostate cancer: a review of the current literature and discussion of practical aspects of therapy","volume":"64","author":"Emmett","year":"2017","journal-title":"J Med Radiat Sci"},{"key":"R15-20250630","doi-asserted-by":"crossref","first-page":"1395","DOI":"10.2967\/jnumed.124.267955","article-title":"Impact of posttreatment SPECT\/CT on patient management during 177Lu-PSMA-617 radiopharmaceutical therapy","volume":"65","author":"Yadav","year":"2024","journal-title":"J Nucl Med"},{"key":"R16-20250630","doi-asserted-by":"crossref","first-page":"1185","DOI":"10.1007\/s00259-023-06536-2","article-title":"Early response monitoring during [177Lu]Lu-PSMA I&T therapy with quantitated SPECT\/CT predicts overall survival of mCRPC patients: subgroup analysis of a Swiss-wide prospective registry study","volume":"51","author":"Neubauer","year":"2024","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R17-20250630","doi-asserted-by":"crossref","first-page":"797","DOI":"10.1016\/S0140-6736(21)00237-3","article-title":"[177Lu] Lu-PSMA-617 versus cabazitaxel in patients with metastatic castration-resistant prostate cancer (TheraP): a randomised, open-label, phase 2 trial","volume":"397","author":"Hofman","year":"2021","journal-title":"Lancet"},{"key":"R18-20250630","doi-asserted-by":"crossref","first-page":"2830","DOI":"10.1007\/s00259-023-06255-8","article-title":"Joint EANM\/SNMMI procedure guideline for the use of 177Lu-labeled PSMA-targeted radioligand-therapy (177Lu-PSMA-RLT)","volume":"50","author":"Kratochwil","year":"2023","journal-title":"Eur J Nucl Med Mol Imaging"},{"key":"R19-20250630","first-page":"1939","article-title":"Comparison of posttherapy 4-and 24-hour [177Lu] Lu-PSMA SPECT\/CT and pretherapy PSMA PET\/CT in assessment of disease in men with metastatic castration-resistant prostate cancer","volume":"65","author":"Swiha","year":"2024","journal-title":"J Nucl Med"},{"key":"R20-20250630","doi-asserted-by":"crossref","first-page":"909","DOI":"10.2967\/jnumed.123.267321","article-title":"Safety and efficacy of extended therapy with [177Lu] Lu-PSMA: a German Multicenter Study","volume":"65","author":"Seifert","year":"2024","journal-title":"J Nucl Med"},{"key":"R21-20250630","doi-asserted-by":"crossref","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","article-title":"New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1)","volume":"45","author":"Eisenhauer","year":"2009","journal-title":"Eur J Cancer"},{"key":"R22-20250630","doi-asserted-by":"crossref","first-page":"1963","DOI":"10.1200\/JCO.19.02757","article-title":"Optimum imaging strategies for advanced prostate cancer: ASCO Guideline","volume":"38","author":"Trabulsi","year":"2020","journal-title":"J Clin Oncol"},{"key":"R23-20250630","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1200\/JCO.2015.64.2702","article-title":"Trial design and objectives for castration-resistant prostate cancer: updated recommendations from the Prostate Cancer Clinical Trials Working Group 3","volume":"34","author":"Scher","year":"2016","journal-title":"J Clin Oncol"},{"key":"R24-20250630","doi-asserted-by":"crossref","first-page":"38","DOI":"10.1038\/s41391-019-0174-x","article-title":"Lutetium-177 prostate-specific membrane antigen (PSMA) theranostics: practical nuances and intricacies","volume":"23","author":"Iravani","year":"2020","journal-title":"Prostate Cancer Prostatic Dis"},{"key":"R25-20250630","doi-asserted-by":"crossref","first-page":"17588359231187202","DOI":"10.1177\/17588359231187202","article-title":"Novel radionuclide therapy combinations in prostate cancer","volume":"15","author":"Inderjeeth","year":"2023","journal-title":"Ther Adv Med Oncol"},{"key":"R26-20250630","doi-asserted-by":"crossref","first-page":"2774","DOI":"10.1158\/1078-0432.CCR-20-0209","article-title":"Mechanistic insights for optimizing PSMA radioligand therapy","volume":"26","author":"Ravi Kumar","year":"2020","journal-title":"Clin Cancer Res"}],"container-title":["Clinical Nuclear Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005986","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,6,30]],"date-time":"2025-06-30T16:01:33Z","timestamp":1751299293000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/RLU.0000000000005986"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,5,21]]},"references-count":26,"journal-issue":{"issue":"8","published-print":{"date-parts":[[2025]]}},"URL":"https:\/\/doi.org\/10.1097\/rlu.0000000000005986","relation":{},"ISSN":["0363-9762","1536-0229"],"issn-type":[{"value":"0363-9762","type":"print"},{"value":"1536-0229","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,5,21]]},"assertion":[{"value":"2024-11-18","name":"received","label":"Received","group":{"name":"publication_history","label":"Publication History"}},{"value":"2025-04-18","name":"accepted","label":"Accepted","group":{"name":"publication_history","label":"Publication History"}}]}}